Literature DB >> 15705086

Validation of the urgency perception scale.

Linda Cardozo1, Karin S Coyne, Eboo Versi.   

Abstract

OBJECTIVE: To ascertain the validity and responsiveness of the Urgency Perception Scale (UPS) as an indicator of perceived urinary urgency. PATIENTS AND METHODS: The UPS was developed to assess perceived urinary urgency in clinical studies evaluating the efficacy of the antimuscarinic drug, tolterodine, for treating the overactive bladder (OAB) syndrome. Secondary analyses of clinical and patient assessment data from three clinical studies of tolterodine were conducted to evaluate the UPS. Construct validity was assessed by correlations between the UPS and patient voiding diary variables and other patient assessments, including: perception of bladder condition; perception of treatment benefit; the Medical Outcomes Study Short-Form 36 health survey; the King's Health Questionnaire; the OAB Questionnaire; and the Overall Treatment Effect scale.
RESULTS: The UPS correlated well with the patients' perception of bladder condition (correlation coefficients - 0.29 to - 0.46; all P < 0.001) and with the voiding diary variables, especially incontinence episodes (-0.30 to - 0.41) and pad usage (-0.25 to - 0.38; all P < 0.001). An improvement in UPS score at the end of treatment was consistently reflected by significant improvements among all voiding variables.
CONCLUSION: Urinary urgency is a central symptom of OAB and is particularly bothersome because of its unpredictability and consequent impact on daily life. The UPS is a valid scale by which urinary urgency can be assessed subjectively, and provides a useful tool for research into urinary urgency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705086     DOI: 10.1111/j.1464-410X.2005.05345.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  30 in total

1.  Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial.

Authors:  Alison J Huang; Rachel Hess; Lily A Arya; Holly E Richter; Leslee L Subak; Catherine S Bradley; Rebecca G Rogers; Deborah L Myers; Karen C Johnson; W Thomas Gregory; Stephen R Kraus; Michael Schembri; Jeanette S Brown
Journal:  Am J Obstet Gynecol       Date:  2012-03-08       Impact factor: 8.661

Review 2.  Fesoterodine for overactive bladder: A review of the literature.

Authors:  Kanchan Gupta; Kirandeep Kaur; Baldev Singh Aulakh; Sandeep Kaushal
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

3.  Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Authors:  Marc R Toglia; Donald R Ostergard; Rodney A Appell; Masakazu Andoh; Allam Fakhoury; Iqbal F Hussain
Journal:  Int Urogynecol J       Date:  2010-03-26       Impact factor: 2.894

Review 4.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 5.  Overactive bladder in the elderly: a guide to pharmacological management.

Authors:  David R Staskin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Measuring urgency in clinical practice.

Authors:  Roger R Dmochowski; Mary P FitzGerald; Jean-Jacques Wyndaele
Journal:  World J Urol       Date:  2009-08-27       Impact factor: 4.226

7.  Cystodistension versus cystoscopy in patients with refractory detrusor overactivity: a randomized controlled trial.

Authors:  Aswini Balachandran; Natasha Curtiss; Maya Basu; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2017-04-24       Impact factor: 2.894

Review 8.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

Review 9.  Basic mechanisms of urgency: roles and benefits of pharmacotherapy.

Authors:  Martin Christian Michel; Christopher R Chapple
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

10.  Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.

Authors:  J J Wyndaele; E R Goldfischer; J D Morrow; J Gong; L J Tseng; Z Guan; M S Choo
Journal:  Int J Clin Pract       Date:  2009-04       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.